“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
Earlier today, InMed Pharmaceuticals (INM) announced that it has signed a definitive agreement to acquire BayMedica, a leading commercial manufacturer of rare cannabinoids. Both companies have strong expertise in the manufacture of rare cannabinoids, with BayMedica largely focused on chemical and biosynthesis and InMed focused on developing IntegraSyn, its proprietary platform. The combined company will be a market leader in rare cannabinoid manufacturing with the flexibility to select the most appropriate and cost-effective method based on each different cannabinoid compound.
In this interview, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss their shared vision for the newly combined company.
Get access to the very latest content matched to your personal investment style.
